ENGLEWOOD, Colo., July 20, 2020 /PRNewswire/ -- Ampio
Pharmaceuticals, Inc. (NYSE American: AMPE), a
biopharmaceutical company focused on the development and
advancement of immunology based therapies for prevalent
inflammatory conditions, today announced the publication
"Insights into pediatric multi-system inflammatory syndrome and
COVID-19."
"This newly described syndrome in children," explained Ampio founder and
principle author, Dr. David Bar-Or, MD, "resembles Kawasaki
Disease and exhibits many signs, symptoms and pathology that could
be treated by intravenous AmpionTM either alone or in
combination with intravenous immunoglobulins ("IVIG")." A commentary describing the involvement
of prostaglandins and cytokines in this syndrome and the Ampion
in-vitro experiments demonstrating beneficial effects for the same,
just published in Clinica Chimica Acta: 510 (2020) 121-122, can be
accessed at: https://authors.elsevier.com/c/1bPpm2G2LyTE3. Ampio
continues to evaluate the potential use of Ampion in this condition
as a safe, effective and alternative/addition to existing
therapies.
About Ampio Pharmaceutical
Ampio Pharmaceuticals,
Inc. is a biopharmaceutical company focused on the development and
advancement of immunology-based therapies for prevalent
inflammatory conditions. Ampio's lead drug, Ampion, is backed
by an extensive patent portfolio with intellectual property
protection extending through 2032, and will be eligible for 12-year
FDA market exclusivity upon approval as a novel biologic under the
biologics price competition and innovation act ("BPCIA").
Forward Looking Statements
Ampio's statements in
this press release that are not historical fact, and that relate to
future plans or events, are forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements can be identified by the use of words
such as "believe," "expect," "plan," "anticipate," and similar
expressions. These forward-looking statements include statements
regarding Ampio's expectations with respect to Ampion and its
classification, as well as those associated with regulatory
approvals and other FDA decisions, the Biological License
Application ("BLA"), the ability of Ampio to enter into
partnering arrangements, clinical trials and decisions and
changes in business conditions and similar events, the ability to
receive regulatory approval to conduct clinical trials, that Ampion
may be used to treat acute respiratory distress syndrome ("ARDS")
induced by COVID-19, all of which are inherently subject to various
risks and uncertainties. The risks and uncertainties involved
include those detailed from time to time in Ampio's filings with
the Securities and Exchange Commission, including without
limitation, under Ampio's Annual Report on Form 10-K and other
documents filed with the Securities and Exchange Commission. Ampio
undertakes no obligation to revise or update these forward-looking
statements, whether as a result of new information, future events
or otherwise.
Company Contact
Dan Stokely, CFO
Phone: (720) 437-6500
info@ampiopharma.com
Ampio Pharmaceuticals, Inc.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/ampio-reports-a-publication-on-the-potential-benefits-of-ampion-for-treatment-of-a-new-covid-19-related-syndrome-301095931.html
SOURCE Ampio Pharmaceuticals, Inc.